January 20, 2015
Meiji Seika Pharma announced on January 19 that the company and Solasia Pharma K.K. have entered into a domestic license agreement to develop and commercialize darinaparsin (IV formulation), which is currently being developed by Solasia for the treatment of relapsed...read more